Sonnet BioTherapeutics (SONN) News Today $1.23 -0.05 (-3.91%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Sonnet Releases Virtual Investor "What This Means" SegmentApril 16 at 9:10 AM | globenewswire.comSonnet BioTherapeutics (NASDAQ:SONN) Earns "Buy" Rating from Chardan CapitalApril 9, 2025 | americanbankingnews.comSonnet BioTherapeutics reports positive results from ovarian cancer therapy trialApril 7, 2025 | msn.comSonnet BioTherapeutics Reports Positive Phase 1b/2a Data For SON-1010April 6, 2025 | nasdaq.comSonnet BioTherapeutics advances in cancer trialApril 6, 2025 | uk.investing.comSonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at ...April 6, 2025 | seekingalpha.comSonnet Biotherapeutics Holdings Inc trading halted, news pendingApril 4, 2025 | markets.businessinsider.comSonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab comboApril 4, 2025 | markets.businessinsider.comSonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest DoseApril 4, 2025 | globenewswire.comSonnet BioTherapeutics appoints interim CEO and new presidentApril 3, 2025 | investing.comSonnet BioTherapeutics Names Raghu Rao Interim CEO As Founder PassesApril 3, 2025 | nasdaq.comPilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech CompanyApril 3, 2025 | msn.comPilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech CompanyApril 2, 2025 | msn.comSonnet BioTherapeutics announces passing of founder, CEO Pankaj MohanApril 2, 2025 | markets.businessinsider.comSonnet Announces Release of Corporate Update VideoApril 1, 2025 | globenewswire.comPilot killed in N.J. plane crash was biotech company founder, CEOApril 1, 2025 | nj.comSonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.April 1, 2025 | globenewswire.comSonnet BioTherapeutics completes first safety review of SON-1010March 27, 2025 | markets.businessinsider.comSonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain SarcomasMarch 26, 2025 | globenewswire.comSonnet BioTherapeutics receives notice of allowance for U.S. patent for IL-18March 20, 2025 | markets.businessinsider.comSonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant ProteinMarch 19, 2025 | globenewswire.comVirtual Investor Releases Next Wave of "Top 5 for '25" On-Demand VideosMarch 11, 2025 | markets.businessinsider.comSonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceMarch 11, 2025 | globenewswire.comSonnet BioTherapeutics presents data on SON-1010February 26, 2025 | markets.businessinsider.comSonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid TumorsFebruary 26, 2025 | globenewswire.comSonnet announces ADC platform available for drug discovery partnershipsFebruary 19, 2025 | markets.businessinsider.comSonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug CandidatesFebruary 19, 2025 | globenewswire.comSonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO ConferenceFebruary 18, 2025 | globenewswire.comSonnet BioTherapeutics appoints McAndrew as Chief Business OfficerFebruary 13, 2025 | markets.businessinsider.comSonnet BioTherapeutics reports Q1 EPS ($1.56) vs ($2.46) last yearFebruary 13, 2025 | markets.businessinsider.comSonnet BioTherapeutics appoints new chief business officerFebruary 13, 2025 | msn.comSonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business OfficerFebruary 13, 2025 | globenewswire.comSonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings UpdateFebruary 13, 2025 | globenewswire.comSonnet BioTherapeutics further expands global IP portfolioJanuary 30, 2025 | markets.businessinsider.comSonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform TechnologyJanuary 28, 2025 | globenewswire.comSonnet BioTherapeutics files to sell 2M shares of common stock for holdersJanuary 23, 2025 | markets.businessinsider.comSonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumoursJanuary 23, 2025 | msn.comSonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarJanuary 22, 2025 | globenewswire.comSonnet BioTherapeutics expands Phase 1 SB101 trialJanuary 21, 2025 | markets.businessinsider.comSonnet BioTherapeutics begins trial combining SON-1010, trabectedinJanuary 21, 2025 | msn.comSonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain SarcomasJanuary 21, 2025 | globenewswire.comSonnet BioTherapeutics Announces Release of the Next CEO Corner SegmentDecember 23, 2024 | globenewswire.comSonnet BioTherapeutics sees cash runway into July 2025December 18, 2024 | markets.businessinsider.comSonnet BioTherapeutics reports FY24 EPS ($11.35) vs. ($145.13) last yearDecember 17, 2024 | markets.businessinsider.comInsights into Sonnet BioTherapeutics Q4 EarningsDecember 17, 2024 | benzinga.comSonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateDecember 17, 2024 | globenewswire.comSonnet announces safety data following SON-1010 monotherapy dose escalationDecember 10, 2024 | markets.businessinsider.comSonnet BioTherapeutics announces $3.9M registered direct offeringDecember 9, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces Positive Topline Safety Data Of SON-1010 At Highest Dose, Stock UpDecember 9, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesDecember 9, 2024 | globenewswire.com Remove Ads Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address SONN Media Mentions By Week SONN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SONN News Sentiment▼-0.130.79▲Average Medical News Sentiment SONN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SONN Articles This Week▼21▲SONN Articles Average Week Remove Ads Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lakeshore Biopharma News Today Unity Biotechnology News Today BriaCell Therapeutics News Today Eagle Pharmaceuticals News Today BioVie News Today MetaVia News Today Cingulate News Today MIRA Pharmaceuticals News Today GeoVax Labs News Today NeuroSense Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SONN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SONN Stock Free SONN Stock Alerts